Literature DB >> 6097410

Intraphagocytic bactericidal activity of bacterial DNA gyrase inhibitors against Serratia marcescens.

W H Traub.   

Abstract

Addition of phenylbutazone (2 mg/ml) to 55 vol% of fresh defibrinated human blood permitted leukocytic ingestion of Serratia marcescens bacteria, but blocked phagocytic killing activity. The group A (phage tail) bacteriocin bA+ 16 served to kill extraphagocytic test bacteria. Five bacterial DNA gyrase inhibitors (ciprofloxacin, enoxacin, norfloxacin, nalidixic acid and pipemidic acid) revealed intraphagocytic bactericidal activity against ingested S. marcescens bacteria of three test strains; the extent of intraphagocytic activity of these drugs approximated that of rifampin. Following combination with unmodified defibrinated human blood (55 vol%), ciprofloxacin, enoxacin, norfloxacin and pipemidic acid yielded additive effects against 3 assay strains of S. marcescens and Escherichia coli strain ATCC 25922; nalidixic acid was inferior in this regard. These data might guide chemotherapy of parenchymatous urinary tract infections.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6097410     DOI: 10.1159/000238297

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  13 in total

1.  Intracellular bactericidal activity of fosfomycin against staphylococci: a comparison with other antibiotics.

Authors:  M Trautmann; C Meincke; K Vogt; M Ruhnke; A M Lajous-Petter
Journal:  Infection       Date:  1992 Nov-Dec       Impact factor: 3.553

2.  The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro.

Authors:  J S Wolfson; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

3.  Fluorometric measurement of ofloxacin uptake by human polymorphonuclear leukocytes.

Authors:  A Pascual; I Garcia; E J Perea
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

4.  Serum bactericidal activity of two newer quinolones against Salmonella typhi compared with standard therapeutic regimens.

Authors:  M Trautmann; B Krause; D Birnbaum; J Wagner; V Lenk
Journal:  Eur J Clin Microbiol       Date:  1986-06       Impact factor: 3.267

5.  Intraphagocytic activity of ciprofloxacin and CI 934.

Authors:  D Milatovic
Journal:  Eur J Clin Microbiol       Date:  1986-12       Impact factor: 3.267

6.  Determination of pipemidic acid in plasma by normal-phase high-pressure liquid chromatography.

Authors:  H Ito; M Inoue; M Morikawa; M Tsuboi; K Oka
Journal:  Antimicrob Agents Chemother       Date:  1985-08       Impact factor: 5.191

7.  Correlation between in vitro and in vivo activity of antimicrobial agents against gram-negative bacilli in a murine infection model.

Authors:  B Fantin; J Leggett; S Ebert; W A Craig
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

8.  Modification of immune response in mice by ciprofloxacin.

Authors:  M Jimenez-Valera; A Sampedro; E Moreno; A Ruiz-Bravo
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

9.  Is pelvic inflammatory disease an indication for treatment with ciprofloxacin?

Authors:  D Hägele; V Chyský
Journal:  Infection       Date:  1988       Impact factor: 3.553

Review 10.  Clinical pharmacokinetics of the newer antibacterial 4-quinolones.

Authors:  M Neuman
Journal:  Clin Pharmacokinet       Date:  1988-02       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.